(Transcript) 2025 LeadershIP Conference Panel IV: Architecting the Future: Call to Action for Innovation Policy

April 4, 2025

This transcript is from the 2025 LeadershIP Conference hosted at CSIS on April 1st, 2025. Watch the full video here.

(DOWNLOAD) LeadershIP 2025 – Panel IV Transcript

Panel Description: There are several legislative proposals on the table today affecting IP, antitrust, and competition. Is more (or less) needed to establish a holistic innovation policy regime that prepares us for the future?

Speakers

Jamie Simpson, Chief Policy Officer and Counsel, Council for Innovation Promotion (C4IP)

Hon. Makan Delrahim, Partner, Latham & Watkins

Judge Paul Michel, Court of Appeals for the Federal Circuit (Ret.)

Adam Mossoff, Professor of Law, Antonin Scalia Law School, George Mason University

Brian Pomper, Partner, Akin Gump

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

October 13, 2025

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

September 9, 2025

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,

If Private Sector R&D Is the Future, IP Policy Must Catch Up

September 8, 2025

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely